Growing prevalence of blindness in the U.S. due to uveitis has led to surge in demand for corticosteroid as the first-line therapy for the treatment of uveitis. The leading players are mainly improving their product portfolio by introducing new range of drugs in the global market. Moreover, as the process for sterile formulations is challenging, companies are mainly inclined to get aligned with regulatory guidelines and GMP in order to manufacture their products.
Factors Propelling Growth of the Global Market
Surge in autoimmune disorders is likely to generate demand for uveitis, the market has witnessed robust emergence of therapies that are immunosuppressive to treat uveitis. With the emergence of such therapies, the market players find good opportunities in the coming years. In addition, due to increasing prevalence of uveitis, various projects related to biological drug development will impact growth of the global uveitis treatment market positively in the coming years. Increasing research and development activities in the field of growing optometric clinical practices will further fuel growth of the global uveitis market in the coming years. In addition, increasing prevalence of TB related to immediate uveitis will further offer opportunities, which will rev up demand for treatment of the uveitis market over the coming years.
Furthermore, surge in demand for implants of local steroid, particularly for posterior uveitis that is non-infectious is a significant trend among others. Moreover, shift in preference from corticosteroid mono-therapy as a first line treatment for uveitis will further fuel growth of the global uveitis treatment market in the span of next seven years. Adding to the list of trends, surge in demand for generic drugs will generate a range of opportunities for new as well as established market players. Such factors are likely to propel growth of the global uveitis treatment market in the coming years. DE-109 (phase III) is mainly manufactured and allocated as the orphan drug by European and the U.S. governing authorities for the treatment of non-infectious posterior uveitis.
Corticosteroid among other types of treatment will remain major segment, followed by monoclonal antibodies and antibiotics. Corticosteroid is likely to retain dominance in the end of 2024, accounting for a market share of over 21%. Anterior uveitis segment among other types of diseases will retain dominance in the span of next seven years in the global uveitis treatment market. Infectious uveitis among various causes will represent the largest segment, accounting for over 87% in the global uveitis treatment market over the coming years. Whereas, hospital pharmacies will account for revenue share of over 46% by the end of 2024.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3596
North America among other regions will exceed US$ 270 Mn in the span of next seven years. In addition, the market in the region will represent a surge in the absolute dollar opportunity over the coming years. The uveitis treatment market in APAC will witness a growth of 6.7% CAGR, and will exceed market value of US$ 190 Mn in the span of next seven years. China will represent relatively fast growing market in the uveitis treatment market in the coming years. The U.S. uveitis treatment market in North America will witness growth in terms of revenue, which will grow 1.8X by the end of 2024 as compared to 2016. Whereas, Canada among other countries of the U.S. will contribute significantly towards the growth of global uveitis treatment market in the coming year. Further, Canada will account for a market value of US$ 50 Mn in the span of next seven years. Canada among other countries in North America will witness a growth of 6.3% CAGR over the coming years.